plgf elisa kit Search Results


human plgf quantikine hs elisa kit  (Bio-Techne corporation)
90
Bio-Techne corporation human plgf quantikine hs elisa kit
Human Plgf Quantikine Hs Elisa Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/Human+PlGF+Quantikine+HS+ELISA+Kit/bio-techne+corporation___hspg00
Average 90 stars, based on 1 article reviews
human plgf quantikine hs elisa kit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
pgf  (R&D Systems)
95
R&D Systems pgf
Pgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/Human+PlGF+Quantikine+ELISA+Kit/10__1161_slash_hypertensionaha__122__20739-66-49-50
Average 95 stars, based on 1 article reviews
pgf - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
human plgf quantikine elisa kit  (R&D Systems)
95
R&D Systems human plgf quantikine elisa kit
Figure 4. (A) MBG-induced decreased expression of VEGF was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (B) MBG-induced decreased expression of <t>PlGF</t> was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (C) MBG-induced increased expression of sFlt-1 was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (D) MBG-induced increased expression of sEng was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05).
Human Plgf Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/Human+PlGF+Quantikine+ELISA+Kit/pm40299324-107-31-50
Average 95 stars, based on 1 article reviews
human plgf quantikine elisa kit - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
mouse quantikine elisa kits  (R&D Systems)
99
R&D Systems mouse quantikine elisa kits
Figure 4. (A) MBG-induced decreased expression of VEGF was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (B) MBG-induced decreased expression of <t>PlGF</t> was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (C) MBG-induced increased expression of sFlt-1 was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (D) MBG-induced increased expression of sEng was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05).
Mouse Quantikine Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/Mouse+PlGF-2+Quantikine+ELISA+Kit/10__1097_slash_hjh__0000000000002528-74-9-13
Average 99 stars, based on 1 article reviews
mouse quantikine elisa kits - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
okbb00242 aviva systems biology  (Aviva Systems)
91
Aviva Systems okbb00242 aviva systems biology
Figure 4. (A) MBG-induced decreased expression of VEGF was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (B) MBG-induced decreased expression of <t>PlGF</t> was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (C) MBG-induced increased expression of sFlt-1 was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (D) MBG-induced increased expression of sEng was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05).
Okbb00242 Aviva Systems Biology, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/PLGF+ELISA+Kit+(Human)+%3A+96+Wells+(OKBB00242)/pmc07765505-189-0-1
Average 91 stars, based on 1 article reviews
okbb00242 aviva systems biology - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
human plgf enzyme linked immunoassay kit technique  (Cusabio)
92
Cusabio human plgf enzyme linked immunoassay kit technique
Figure 4. (A) MBG-induced decreased expression of VEGF was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (B) MBG-induced decreased expression of <t>PlGF</t> was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (C) MBG-induced increased expression of sFlt-1 was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (D) MBG-induced increased expression of sEng was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05).
Human Plgf Enzyme Linked Immunoassay Kit Technique, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/Human+placenta+growth+factor%2CPLGF+ELISA+kit/10__4103_slash_mj__mj_8_18-81-13-12
Average 92 stars, based on 1 article reviews
human plgf enzyme linked immunoassay kit technique - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
ripa buffer  (R&D Systems)
93
R&D Systems ripa buffer
Figure 4. (A) MBG-induced decreased expression of VEGF was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (B) MBG-induced decreased expression of <t>PlGF</t> was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (C) MBG-induced increased expression of sFlt-1 was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (D) MBG-induced increased expression of sEng was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05).
Ripa Buffer, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/Mouse+PlGF-2+Quantikine+ELISA+Kit/pmc08511710-54-4-19
Average 93 stars, based on 1 article reviews
ripa buffer - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
plgf  (Cusabio)
93
Cusabio plgf
Various vascular markers for type C PCV, CSCR, and nvAMD. Before intravitreous injection (IVI), aqueous protein levels of <t>VEGF/PlGF/HIF-1α/β-catenin/Wnt1</t> were detected <t>using</t> <t>ELISA</t> on patients with AMD, PCV, or CSCR. In ( A ), the PCV ( n = 17) or nvAMD ( n = 41; control) levels of VEGF were median [Q1, Q3]: 106.19 [80.00, 203.81] or 191.91 [116.68, 289.96]. In ( B ), the PCV ( n = 13) or nvAMD ( n = 29) levels of PlGF were median [Q1, Q3]: 1.39 [0.72, 18.45] or 15.48 [11.25, 17.90]. The PCV/CSCR/nvAMD (pre-IVI; n = 9/4/16) levels of β-catenin ( C ) were 983.77 ± 329.68/1224.33 ± 743.69/3622.41 ± 499.70. The PCV/CSCR/nvAMD (pre-IVI; n = 5/4/20) levels of HIF-1α ( D ) were median [Q1, Q3]: 6096.66/8705.06/1091.28 [5173.83/5939.04/803.69, 7811.37/14,239.77/3210.46]. Additionally, the PCV/CSCR (pre-IVI) levels of Wnt1 ( E ) were 1180.66 ± 172.41 ( n = 6)/1387.12 ± 289.54 ( n = 4). Significance was * p < 0.05.
Plgf, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/Rat+placenta+growth+factor%2CPLGF+ELISA+kit/pmc12897784-186-20-22
Average 93 stars, based on 1 article reviews
plgf - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
koa0292  (Rockland Immunochemicals)
94
Rockland Immunochemicals koa0292
Various vascular markers for type C PCV, CSCR, and nvAMD. Before intravitreous injection (IVI), aqueous protein levels of <t>VEGF/PlGF/HIF-1α/β-catenin/Wnt1</t> were detected <t>using</t> <t>ELISA</t> on patients with AMD, PCV, or CSCR. In ( A ), the PCV ( n = 17) or nvAMD ( n = 41; control) levels of VEGF were median [Q1, Q3]: 106.19 [80.00, 203.81] or 191.91 [116.68, 289.96]. In ( B ), the PCV ( n = 13) or nvAMD ( n = 29) levels of PlGF were median [Q1, Q3]: 1.39 [0.72, 18.45] or 15.48 [11.25, 17.90]. The PCV/CSCR/nvAMD (pre-IVI; n = 9/4/16) levels of β-catenin ( C ) were 983.77 ± 329.68/1224.33 ± 743.69/3622.41 ± 499.70. The PCV/CSCR/nvAMD (pre-IVI; n = 5/4/20) levels of HIF-1α ( D ) were median [Q1, Q3]: 6096.66/8705.06/1091.28 [5173.83/5939.04/803.69, 7811.37/14,239.77/3210.46]. Additionally, the PCV/CSCR (pre-IVI) levels of Wnt1 ( E ) were 1180.66 ± 172.41 ( n = 6)/1387.12 ± 289.54 ( n = 4). Significance was * p < 0.05.
Koa0292, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/Human+PLGF+ELISA+Kit/10__1002_slash_btm2__70114-258-28-25
Average 94 stars, based on 1 article reviews
koa0292 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
rat plgf elisa microplate kit mbs703282  (MyBiosource Biotechnology)
90
MyBiosource Biotechnology rat plgf elisa microplate kit mbs703282
Various vascular markers for type C PCV, CSCR, and nvAMD. Before intravitreous injection (IVI), aqueous protein levels of <t>VEGF/PlGF/HIF-1α/β-catenin/Wnt1</t> were detected <t>using</t> <t>ELISA</t> on patients with AMD, PCV, or CSCR. In ( A ), the PCV ( n = 17) or nvAMD ( n = 41; control) levels of VEGF were median [Q1, Q3]: 106.19 [80.00, 203.81] or 191.91 [116.68, 289.96]. In ( B ), the PCV ( n = 13) or nvAMD ( n = 29) levels of PlGF were median [Q1, Q3]: 1.39 [0.72, 18.45] or 15.48 [11.25, 17.90]. The PCV/CSCR/nvAMD (pre-IVI; n = 9/4/16) levels of β-catenin ( C ) were 983.77 ± 329.68/1224.33 ± 743.69/3622.41 ± 499.70. The PCV/CSCR/nvAMD (pre-IVI; n = 5/4/20) levels of HIF-1α ( D ) were median [Q1, Q3]: 6096.66/8705.06/1091.28 [5173.83/5939.04/803.69, 7811.37/14,239.77/3210.46]. Additionally, the PCV/CSCR (pre-IVI) levels of Wnt1 ( E ) were 1180.66 ± 172.41 ( n = 6)/1387.12 ± 289.54 ( n = 4). Significance was * p < 0.05.
Rat Plgf Elisa Microplate Kit Mbs703282, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/rat+plgf+elisa+microplate+kit+mbs703282/pmc05142222-93-6-12
Average 90 stars, based on 1 article reviews
rat plgf elisa microplate kit mbs703282 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
plgf (placenta like growth factor) elisa kit  (DRG International)
90
DRG International plgf (placenta like growth factor) elisa kit
Various vascular markers for type C PCV, CSCR, and nvAMD. Before intravitreous injection (IVI), aqueous protein levels of <t>VEGF/PlGF/HIF-1α/β-catenin/Wnt1</t> were detected <t>using</t> <t>ELISA</t> on patients with AMD, PCV, or CSCR. In ( A ), the PCV ( n = 17) or nvAMD ( n = 41; control) levels of VEGF were median [Q1, Q3]: 106.19 [80.00, 203.81] or 191.91 [116.68, 289.96]. In ( B ), the PCV ( n = 13) or nvAMD ( n = 29) levels of PlGF were median [Q1, Q3]: 1.39 [0.72, 18.45] or 15.48 [11.25, 17.90]. The PCV/CSCR/nvAMD (pre-IVI; n = 9/4/16) levels of β-catenin ( C ) were 983.77 ± 329.68/1224.33 ± 743.69/3622.41 ± 499.70. The PCV/CSCR/nvAMD (pre-IVI; n = 5/4/20) levels of HIF-1α ( D ) were median [Q1, Q3]: 6096.66/8705.06/1091.28 [5173.83/5939.04/803.69, 7811.37/14,239.77/3210.46]. Additionally, the PCV/CSCR (pre-IVI) levels of Wnt1 ( E ) were 1180.66 ± 172.41 ( n = 6)/1387.12 ± 289.54 ( n = 4). Significance was * p < 0.05.
Plgf (Placenta Like Growth Factor) Elisa Kit, supplied by DRG International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/plgf++placenta+like+growth+factor++elisa+kit/pm22429154-46-31-43
Average 90 stars, based on 1 article reviews
plgf (placenta like growth factor) elisa kit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human plgf quantikine elisa kit catalogue number dpg00  (Becton Dickinson)
90
Becton Dickinson human plgf quantikine elisa kit catalogue number dpg00
Various vascular markers for type C PCV, CSCR, and nvAMD. Before intravitreous injection (IVI), aqueous protein levels of <t>VEGF/PlGF/HIF-1α/β-catenin/Wnt1</t> were detected <t>using</t> <t>ELISA</t> on patients with AMD, PCV, or CSCR. In ( A ), the PCV ( n = 17) or nvAMD ( n = 41; control) levels of VEGF were median [Q1, Q3]: 106.19 [80.00, 203.81] or 191.91 [116.68, 289.96]. In ( B ), the PCV ( n = 13) or nvAMD ( n = 29) levels of PlGF were median [Q1, Q3]: 1.39 [0.72, 18.45] or 15.48 [11.25, 17.90]. The PCV/CSCR/nvAMD (pre-IVI; n = 9/4/16) levels of β-catenin ( C ) were 983.77 ± 329.68/1224.33 ± 743.69/3622.41 ± 499.70. The PCV/CSCR/nvAMD (pre-IVI; n = 5/4/20) levels of HIF-1α ( D ) were median [Q1, Q3]: 6096.66/8705.06/1091.28 [5173.83/5939.04/803.69, 7811.37/14,239.77/3210.46]. Additionally, the PCV/CSCR (pre-IVI) levels of Wnt1 ( E ) were 1180.66 ± 172.41 ( n = 6)/1387.12 ± 289.54 ( n = 4). Significance was * p < 0.05.
Human Plgf Quantikine Elisa Kit Catalogue Number Dpg00, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plgf+elisa+kit/human+plgf+quantikine+elisa+kit+catalogue+number+dpg00/10__1002_slash_jper__17___0497-78-3-1
Average 90 stars, based on 1 article reviews
human plgf quantikine elisa kit catalogue number dpg00 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Figure 4. (A) MBG-induced decreased expression of VEGF was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (B) MBG-induced decreased expression of PlGF was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (C) MBG-induced increased expression of sFlt-1 was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (D) MBG-induced increased expression of sEng was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05).

Journal: Biomedicines

Article Title: Neutralization of Marinobufagenin Demonstrates Efficacy In Vitro and In Vivo in Models of Pre-Eclampsia.

doi: 10.3390/biomedicines13040782

Figure Lengend Snippet: Figure 4. (A) MBG-induced decreased expression of VEGF was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (B) MBG-induced decreased expression of PlGF was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (C) MBG-induced increased expression of sFlt-1 was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05). (D) MBG-induced increased expression of sEng was attenuated by pretreatment with H3L2 (4 µg/mL) (* p < 0.05).

Article Snippet: Measurement of angiogenic factors: Levels of the pro-angiogenic factors VEGF and PlGF, and the anti-angiogenic factors sFlt-1 and sEng, were measured with commercially available kits (Human VEGF Quantikine ELISA Kit (DVE00); Human PlGF Quantikine ELISA Kit (DPG00); Human sVEGF R1/Flt-1 Quantikine ELISA Kit (DVR100B); Human Endoglin/CD105 Quantikine ELISA Kit (DNDG00); R&D Systems, Minneapolis, MN, USA).

Techniques: Expressing

Various vascular markers for type C PCV, CSCR, and nvAMD. Before intravitreous injection (IVI), aqueous protein levels of VEGF/PlGF/HIF-1α/β-catenin/Wnt1 were detected using ELISA on patients with AMD, PCV, or CSCR. In ( A ), the PCV ( n = 17) or nvAMD ( n = 41; control) levels of VEGF were median [Q1, Q3]: 106.19 [80.00, 203.81] or 191.91 [116.68, 289.96]. In ( B ), the PCV ( n = 13) or nvAMD ( n = 29) levels of PlGF were median [Q1, Q3]: 1.39 [0.72, 18.45] or 15.48 [11.25, 17.90]. The PCV/CSCR/nvAMD (pre-IVI; n = 9/4/16) levels of β-catenin ( C ) were 983.77 ± 329.68/1224.33 ± 743.69/3622.41 ± 499.70. The PCV/CSCR/nvAMD (pre-IVI; n = 5/4/20) levels of HIF-1α ( D ) were median [Q1, Q3]: 6096.66/8705.06/1091.28 [5173.83/5939.04/803.69, 7811.37/14,239.77/3210.46]. Additionally, the PCV/CSCR (pre-IVI) levels of Wnt1 ( E ) were 1180.66 ± 172.41 ( n = 6)/1387.12 ± 289.54 ( n = 4). Significance was * p < 0.05.

Journal: International Journal of Molecular Sciences

Article Title: Combined Therapy Versus Fortified Anti-VEGF Monotherapy in Type C Polypoidal Choroidal Vasculopathy: Long-Term Outcomes and Exploratory Biomarker Insights †

doi: 10.3390/ijms27031224

Figure Lengend Snippet: Various vascular markers for type C PCV, CSCR, and nvAMD. Before intravitreous injection (IVI), aqueous protein levels of VEGF/PlGF/HIF-1α/β-catenin/Wnt1 were detected using ELISA on patients with AMD, PCV, or CSCR. In ( A ), the PCV ( n = 17) or nvAMD ( n = 41; control) levels of VEGF were median [Q1, Q3]: 106.19 [80.00, 203.81] or 191.91 [116.68, 289.96]. In ( B ), the PCV ( n = 13) or nvAMD ( n = 29) levels of PlGF were median [Q1, Q3]: 1.39 [0.72, 18.45] or 15.48 [11.25, 17.90]. The PCV/CSCR/nvAMD (pre-IVI; n = 9/4/16) levels of β-catenin ( C ) were 983.77 ± 329.68/1224.33 ± 743.69/3622.41 ± 499.70. The PCV/CSCR/nvAMD (pre-IVI; n = 5/4/20) levels of HIF-1α ( D ) were median [Q1, Q3]: 6096.66/8705.06/1091.28 [5173.83/5939.04/803.69, 7811.37/14,239.77/3210.46]. Additionally, the PCV/CSCR (pre-IVI) levels of Wnt1 ( E ) were 1180.66 ± 172.41 ( n = 6)/1387.12 ± 289.54 ( n = 4). Significance was * p < 0.05.

Article Snippet: Protein levels in aqueous humor were quantified using commercial ELISA kits [ , ]: VEGF (BMS227/2, Bender MedSystems, Wien, Austria), PlGF (CBS-E07400r, Cusabio, Houston, TX 77054, USA), HIF-1α (M00013-2, Uscn Life Science, San Jose, CA 95123, USA), β-catenin (DYC1329, R&D Systems, Minneapolis, MN 55413, USA), and Wnt1 (RHF128CK, Antigenix America, Huntington Station, NY 11746, USA) [ ].

Techniques: Injection, Enzyme-linked Immunosorbent Assay, Control